Trials / Approved For Marketing
Approved For MarketingNCT00071708
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.
Conditions
- Major Depressive Disorder
- Fibromyalgia
- Diabetic Peripheral Neuropathic Pain
- Generalized Anxiety Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duloxetine Hydrochloride |
Timeline
- First posted
- 2003-10-30
- Last updated
- 2025-01-10
Locations
13 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00071708. Inclusion in this directory is not an endorsement.